Secondary win-ratio analysis of a randomised trial in cancer-associated VTE (522 edoxaban vs 524 dalteparin): across 10 ranked outcomes there was no significant difference at 12 months (win ratio 0.91, 95% CI 0.76–1.08).
RCTn = 1,046
van Es et al. The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial